Skip to main content
. Author manuscript; available in PMC: 2022 May 7.
Published in final edited form as: Diabetes Metab Res Rev. 2020 Apr 3;36(6):e3310. doi: 10.1002/dmrr.3310

TABLE 6.

Meta-analysis of propensity score adjusted, not matched analyses

95% CI
Not matched N OR Lo Hi P < Investigators
Specific statin:
 Atorvastatin× 1065 2.80 1.74 4.49 .001 Chen et al74
 Pravastatin 3.41 1.66 7.04 0.001 .001 Chen et al74
 Rosuvastatin 4.69 2.78 7.92 0.001 .001 Chen et al74
 Simvastatin 4.09 2.52 6.64 0.001 .001 Chen et al74
Any statin 4460 1.19 1.05 1.35 .007 Castro et al75
Any statin 7076 1.43 1.28 1.58 .05 Culver et al49
Any statin 2 016 094 1.57 1.54 1.59 .01 Macedo76
Any statin 53 212 2.07 1.77 2.42 .0001 Olotu et al77
 Atorvastatin 27 155 1.95 1.62 2.35 .0001 Olotu et al77
 Fluvastatin 1638 1.95 1.28 2.96 .003 Olotu et al77
 Lovastatin 3570 2.45 1.82 3.25 .0001 Olotu et al77
 Pravastatin 5870 1.40 1.04 1.87 .0001 Olotu et al77
 Rosuvastatin 2766 1.75 1.19 2.56 .0001 Olotu et al77
 Simvastatin 12 213 1.79 1.43 2.24 .0001 Olotu et al77
95% CI
Meta-analysis OR lo hi Z P <
Fixed 1.66 1.59 1.74 21.34 .0001
Random 2.23 1.76 2.84 6.617 .0001
Heterogeneity
Q-value Q df P-value I-squared
214.349 10 <.0001 95.335
Tau squared SE Variance Tau
0.148 0.096 0.009 0.385
HHS Vulnerability Disclosure